Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927022 | 0.88 | SMN1; SMN2 (0.44) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL13930871 | 0.87 | MEN1 (0.52) | ESR1ESR2MEN1KMT2ACYP19A1 | |
| SCHEMBL7041297 | 0.84 | KMT2A (0.44) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL7041299 | 0.84 | ESR1 (0.47) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL15478368 | 0.82 | MEN1 (0.42) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL19592942 | 0.81 | SMN1; SMN2 (0.41) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL10179124 | 0.81 | MEN1 (0.44) | ESR1ESR2MEN1KMT2ACYP19A1 | |
| SCHEMBL24004027 | 0.79 | ESR1 (0.50) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL22654049 | 0.79 | MEN1 (0.50) | ESR1ESR2MEN1KMT2ACYP19A1 | |
| SCHEMBL21164691 | 0.79 | ESR1 (0.46) | ESR1ESR2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20110312997-A1 | Inhibition of WDR5 Interaction with Its Binding Partners | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | ESR1 4768/4885ESR2 4317/4885MEN1 2824/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | ESR1 2290/4885ESR2 693/4885MEN1 3010/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ESR1 2700/4885ESR2 1201/4885MEN1 2234/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ESR1 2700/4885ESR2 1201/4885MEN1 2234/4885 |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ESR1 2290/4885ESR2 693/4885MEN1 3010/4885 |
| US-20110312997-A1 | Inhibition of WDR5 Interaction with Its Binding Partners | WDR5, WDR77, WDR1 | ESR1 2980/4885ESR2 2724/4885MEN1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.